|
60 Companies |
|
66 Products |
|
66 Products |
|
77 Mechanisms of Action |
|
2 Trials |
|
576 News |
|
| «123456789101112» |
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Enrollment change, Epigenetic controller: Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia (clinicaltrials.gov) - Jul 17, 2014
P1, N=27, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=34 --> 27
- ||| Trial completion: Non-invasive Chromosomal Examination of Trisomy Study (clinicaltrials.gov) - Jul 14, 2014
P=N/A, N=18955, Completed, Sponsor: Ariosa Diagnostics, Inc
Active, not recruiting --> Completed | N=34 --> 27 Active, not recruiting --> Completed
- |||| metadoxine extended-release (MG01CI) / Arcturus Therap
Enrollment open: A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome (clinicaltrials.gov) - Jul 12, 2014
P2, N=60, Recruiting, Sponsor: Alcobra Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Turner Syndrome: Genotype and Phenotype (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=1017, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial termination: DHEAFert: Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility (clinicaltrials.gov) - Jul 1, 2014
P2/3, N=35, Terminated, Sponsor: Center for Human Reproduction
Active, not recruiting --> Completed Recruiting --> Terminated; Failure to recruit designed nuimebrt of subjects
- Enrollment change, Trial termination: DHEAFert: Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility (clinicaltrials.gov) - Jul 1, 2014
P2/3, N=35, Terminated, Sponsor: Center for Human Reproduction
Recruiting --> Terminated; Failure to recruit designed nuimebrt of subjects N=220 --> 35 | Recruiting --> Terminated; Failure to recruit designed nuimebrt of subjects
- Clinical: Predicting Normal vs. Carrier Status in Euploid Embryos of Translocation Carriers (clinicaltrials.gov) - Jul 1, 2014
P=N/A, N=100, Recruiting, Sponsor: Reproductive Medicine Associates of New Jersey
- |||||||||| beloranib (ZGN-440) / Larimar Therap
New P3 trial: bestPWS: Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome (clinicaltrials.gov) - Jul 1, 2014
P3, N=84, Not yet recruiting, Sponsor: Zafgen, Inc.
- Enrollment open: Assessment of Bone Density and Bone Turnover Markers in Patients With Down Syndrome and Comparison to the Ts65Dn Model (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=60, Recruiting, Sponsor: University of Arkansas
N=220 --> 35 | Recruiting --> Terminated; Failure to recruit designed nuimebrt of subjects Active, not recruiting --> Recruiting
- ||| Enrollment open: Prenatal Screening for Down Syndrome With DNAFirst (clinicaltrials.gov) - Jun 24, 2014
P=N/A, N=100, Recruiting, Sponsor: Women and Infants Hospital of Rhode Island
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Enrollment open, Trial initiation date: Prenatal Screening for Down Syndrome With DNAFirst (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=100, Not yet recruiting, Sponsor: Women and Infants Hospital of Rhode Island
Not yet recruiting --> Recruiting Initiation date: Nov 2013 --> Mar 2014 | Not yet recruiting --> Recruiting
- Trial primary completion date, CAR T-Cell Therapy: CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant (clinicaltrials.gov) - Jun 12, 2014
P1/2, N=30, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Nov 2013 --> Mar 2014 | Not yet recruiting --> Recruiting Trial primary completion date: Feb 2017 --> Apr 2014
- Clinical: Risk of Diabetes in Young Turner Syndrome Patients (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=120, Recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
- Enrollment closed, CAR T-Cell Therapy: CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant (clinicaltrials.gov) - Jun 12, 2014
P1/2, N=30, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Feb 2017 --> Apr 2014 Recruiting --> Active, not recruiting
- Trial primary completion date: ESHRE-ESTEEM: The Eshre Study Into The Evaluation of Oocyte Euploidy by Microarray Analysis (clinicaltrials.gov) - Jun 5, 2014
P=N/A, N=600, Recruiting, Sponsor: European Society of Human Reproduction and Embryology
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2014 --> Nov 2014
- Clinical: Phenotypic Specific Communication Intervention for Children With Down Syndrome (clinicaltrials.gov) - Jun 4, 2014
P=N/A, N=82, Recruiting, Sponsor: Vanderbilt University
- || Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial primary completion date: ONTARGET: Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (clinicaltrials.gov) - May 25, 2014
P2, N=60, Recruiting, Sponsor: Onconova Therapeutics, Inc.
Trial primary completion date: Jan 2014 --> Nov 2014 Trial primary completion date: Apr 2014 --> Oct 2014
- || Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial completion date: ONTARGET: Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (clinicaltrials.gov) - May 25, 2014
P2, N=60, Recruiting, Sponsor: Onconova Therapeutics, Inc.
Trial primary completion date: Apr 2014 --> Oct 2014 Trial completion date: Oct 2014 --> Mar 2015
- |||| mavoglurant (AFQ056) / Novartis
Trial primary completion date: Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label) (clinicaltrials.gov) - May 20, 2014
P2/3, N=170, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Oct 2014 --> Mar 2015 Trial primary completion date: Dec 2015 --> Aug 2014
- ||| mavoglurant (AFQ056) / Novartis
Trial completion date: Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label) (clinicaltrials.gov) - May 20, 2014
P2/3, N=170, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> Aug 2014 Trial completion date: Dec 2015 --> Aug 2014
- || mavoglurant (AFQ056) / Novartis
Trial primary completion date: Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome (clinicaltrials.gov) - May 20, 2014
P2, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2015 --> Aug 2014 Trial primary completion date: Dec 2015 --> Aug 2014
- || mavoglurant (AFQ056) / Novartis
Trial completion date: Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome (clinicaltrials.gov) - May 20, 2014
P2, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> Aug 2014 Trial completion date: Dec 2015 --> Aug 2014
- ||||| imatinib / Generic mfg., dasatinib / Generic mfg.
Trial initiation date: DASISION: A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (clinicaltrials.gov) - May 19, 2014
P3, N=547, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Dec 2015 --> Aug 2014 Initiation date: Sep 2007 --> Aug 2007
- Biomarker: Down Syndrome Biomarker Initiative (DSBI) (clinicaltrials.gov) - May 18, 2014
P=N/A, N=12, Active, not recruiting, Sponsor: Alzheimer's Disease Cooperative Study (ADCS)
- || metadoxine extended-release (MG01CI) / Arcturus Therap
Trial primary completion date: A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome (clinicaltrials.gov) - May 17, 2014
P2, N=60, Not yet recruiting, Sponsor: Alcobra Ltd.
Initiation date: Sep 2007 --> Aug 2007 Trial primary completion date: Jan 2015 --> Dec 2014
- || basmisanil (RG1662) / Roche
Trial primary completion date: A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS) (clinicaltrials.gov) - May 13, 2014
P2, N=180, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jan 2015 --> Dec 2014 Trial primary completion date: Jan 2016 --> Aug 2015
- Trial primary completion date: Prader-Willi Syndrome Macronutrient Study (clinicaltrials.gov) - May 13, 2014
P=N/A, N=10, Recruiting, Sponsor: Duke University
Trial primary completion date: Jan 2016 --> Aug 2015 Trial primary completion date: Jan 2015 --> Jun 2015
- ||| basmisanil (RG1662) / Roche
Trial initiation date: A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS) (clinicaltrials.gov) - May 13, 2014
P2, N=180, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jan 2015 --> Jun 2015 Initiation date: Mar 2014 --> May 2014
- Trial initiation date: Prader-Willi Syndrome Macronutrient Study (clinicaltrials.gov) - May 13, 2014
P=N/A, N=10, Recruiting, Sponsor: Duke University
Initiation date: Mar 2014 --> May 2014 Initiation date: Jan 2014 --> May 2014
- || basmisanil (RG1662) / Roche
Trial completion date: A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS) (clinicaltrials.gov) - May 13, 2014
P2, N=180, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Jan 2014 --> May 2014 Trial completion date: Jan 2016 --> Aug 2015
- |||| basmisanil (RG1662) / Roche
Enrollment open: A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS) (clinicaltrials.gov) - May 13, 2014
P2, N=180, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jan 2016 --> Aug 2015 Not yet recruiting --> Recruiting
- Enrollment open: Prader-Willi Syndrome Macronutrient Study (clinicaltrials.gov) - May 13, 2014
P=N/A, N=10, Recruiting, Sponsor: Duke University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial primary completion date: Klinefelter Fertility Preservation (clinicaltrials.gov) - May 13, 2014
P=N/A, N=15, Completed, Sponsor: Children's Hospital Boston
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2013 --> Apr 2014
- Enrollment change: Klinefelter Fertility Preservation (clinicaltrials.gov) - May 13, 2014
P=N/A, N=15, Completed, Sponsor: Children's Hospital Boston
Trial primary completion date: Oct 2013 --> Apr 2014 N=20 --> 15
- Trial completion: Klinefelter Fertility Preservation (clinicaltrials.gov) - May 13, 2014
P=N/A, N=15, Completed, Sponsor: Children's Hospital Boston
N=20 --> 15 Recruiting --> Completed
- |||| mavoglurant (AFQ056) / Novartis
Trial completion: Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome (clinicaltrials.gov) - May 11, 2014
P2, N=139, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed
- |||| basimglurant (NOE-101) / Noema Pharma
Trial completion: A Study of RO4917523 in Patients With Fragile X Syndrome (clinicaltrials.gov) - May 11, 2014
P2, N=185, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Active, not recruiting --> Completed
- basmisanil (RG1662) / Roche
Trial initiation date: A Study of RG1662 in Individuals With Down Syndrome (clinicaltrials.gov) - May 11, 2014
P1, N=35, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Initiation date: Jan 2012 --> Nov 2011
- Trial primary completion date: Sex Differences in Early Brain Development; Brain Development in Turner Syndrome (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=295, Completed, Sponsor: University of North Carolina, Chapel Hill
Initiation date: Jan 2012 --> Nov 2011 Trial primary completion date: May 2013 --> May 2014
- Trial completion date: Sex Differences in Early Brain Development; Brain Development in Turner Syndrome (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=295, Completed, Sponsor: University of North Carolina, Chapel Hill
Trial primary completion date: May 2013 --> May 2014 Trial completion date: May 2013 --> May 2014
- Trial completion: Sex Differences in Early Brain Development; Brain Development in Turner Syndrome (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=295, Completed, Sponsor: University of North Carolina, Chapel Hill
Trial completion date: May 2013 --> May 2014 Active, not recruiting --> Completed
- ||||| metadoxine extended-release (MG01CI) / Arcturus Therap
New P2 trial: A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome (clinicaltrials.gov) - Apr 28, 2014
P2, N=60, Not yet recruiting, Sponsor: Alcobra Ltd.
- MK-2206 / Merck (MSD)
Enrollment change: MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia (clinicaltrials.gov) - Apr 27, 2014
P1, N=45, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=96 --> 45
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment closed, Epigenetic controller: Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia (clinicaltrials.gov) - Apr 22, 2014
P1, N=34, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=96 --> 45 Recruiting --> Active, not recruiting
- ||| imatinib / Generic mfg., dasatinib / Generic mfg.
Trial completion date: DASISION: A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (clinicaltrials.gov) - Apr 21, 2014
P3, N=547, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Trial completion date: Dec 2013 --> Dec 2015
- diazoxide choline controlled release (DCCR) / Soleno Therap
Enrollment open: Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome (clinicaltrials.gov) - Apr 20, 2014
P1, N=12, Recruiting, Sponsor: Essentialis, Inc.
Trial completion date: Dec 2013 --> Dec 2015 Not yet recruiting --> Recruiting
- Metastases: Aneuploidy Rates in Advanced Maternal Age Patients Supplemented With Coenzyme Q10 (CoQ10) Versus Those That Are Not: a Pilot Study (clinicaltrials.gov) - Apr 17, 2014
P=N/A, N=30, Recruiting, Sponsor: Reproductive Endocrinology Associates of Charlotte
- Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial primary completion date: Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk (clinicaltrials.gov) - Apr 9, 2014
P2, N=14, Completed, Sponsor: Onconova Therapeutics, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2012 --> Nov 2013
- Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial completion date: Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk (clinicaltrials.gov) - Apr 9, 2014
P2, N=14, Completed, Sponsor: Onconova Therapeutics, Inc.
Trial primary completion date: Aug 2012 --> Nov 2013 Trial completion date: Aug 2012 --> Nov 2013
- Enrollment change: Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 8, 2014
P1, N=7, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial completion date: Aug 2012 --> Nov 2013 N=24 --> 7